Lupin is planning to expand its footprint in Europe by acquiring generics manufacturers for as much as $1 billion. The company is eying those entities that are capable in complex generics like inhalation products and injectables, dermatology products and biosimilar drugs.
Europe is attractive because it has clearer regulations than the US on biosimilars, or copies of biotechnology therapies. Europe contributed 3 percent of Lupin’s sales last year.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1871.55 |
| Dr. Reddys Labs. | 1346.25 |
| Cipla | 1456.25 |
| Zydus Lifesciences | 1099.65 |
| Lupin | 2398.70 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: